Cannabis Stock Releases Huge
News-THC Therapeutics, Inc. (THCT)
May 15, 2019 -- InvestorsHub NewsWire -- Microcap Speculators --
One challenge several upcoming cannabis stocks face is proving they
are ‘for real’. Well, one stock we have been tracking,
THC Therapeutics, Inc. (USOTC:
THCT), just made a major announcement in this
regard. THCT announced Enzo Villani was appointed a
member of the company’s Board of Directors. Mr. Villani is
Co-Founder of Nasdaq Global Corporate Solutions
Group. Mr. Villani has
raised over $500 million in funding from strategic investors,
private equity, venture capital, family offices and the public
markets during his over twenty-year career.
Today we are highlighting: THC Therapeutics, Inc. (USOTC:
THCT), Aphria (NYSE:
APHA), HEXO Corp. (AMEX:
HEXO), Auxly Cannabis Group Inc. (CBWTF), and Cara Therapeutics
(NASDAQ:
CARA).
THC Therapeutics, Inc. (USOTC:
THCT) (Market Cap: $136.195M; Share Price:
$9.89) has developed a sanitizing herb dryer, The
dHydronator®. Their laboratory-proven product is specifically
designed for drying and sanitizing freshly harvested cannabis and
herbs. THCT’s product has been tested by two
independent laboratories. The testing covered over 6 strains
and 9 independent tests to confirm the findings.
Over the 9 tests and 6 strains, there was a 4% average increase of
THC-A*.
THCT’s dHydronator can reduce moisture content
of cannabis to 10% in only 10-14 hours.
This is the same reason Aurora just signed a deal with
EnWave. THCT received patent protection on 20 claims
from the US patent office in March ’19 and will be using their
patented designs to carve out their piece of the legal cannabis
market expected to reach $146.4 billion by 2025.
The company has received full patent protection for the
dHydronator®. Start your research today on
THCT.
________
Aphria Inc. (NYSE:
APHA) (Market Cap: $1.74B; Share Price:
$6.95) shares fell after the Canadian cannabis
company reported fiscal third-quarter results.
It posted a C$108.2 million ($81.1 million) loss for its
fiscal third quarter, or 43 cents a share, after a profit of
C$12.9 million, or 8 cents a share, in the same period a year
ago. Revenue climbed to C$73.6 million from C$10.3 million in
the first full quarter of Canadian legal cannabis. But the
company sold less cannabis than a year ago—kilograms sold fell to
2,636.5 from 3,408.9, while the average retail selling price for
medical cannabis increased to C$8.03 per gram from C$7.51,
primarily because of higher oil sales.
In April, it announced that the previously announced take-over
bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to
meet the statutory minimum tender condition and has now expired and
is terminated. As previously announced on April 15,
2019, the company entered into a definitive agreement with GGB to
accelerate the expiry date of the Offer to April 25, 2019, as well
as to terminate certain arrangements with GA Opportunities Corp.
("GAOC") for consideration of $89.0 million payable on future dates
as set out in the April 15th press release. The Offer is now
expired and terminated and no longer open to any Aphria shareholder
to tender their shares. Accordingly, GGB will not be taking
up any securities that may have been tendered to the Offer.
GGB will promptly return to the securityholder any Aphria shares
tendered and not withdrawn during the period from the commencement
of the Offer up to the expiry time of the Offer.
________
HEXO Corp (AMEX:
HEXO) (Market Cap: $1.454B; Share Price:
$6.85) and Newstrike Brands Ltd. ("Newstrike")
(TSX-V: HIP) had announced in March that they had entered into
a definitive arrangement agreement (the "Arrangement Agreement")
under which HEXO will acquire all of Newstrike’s issued and
outstanding common shares in an all-share transaction valued at
approximately $263 million. The Transaction
gives HEXO the capacity to produce approximately 150,000
kg of high-quality cannabis annually. The Transaction also
provides HEXO access to four cutting-edge production
campuses totalling close to 1.8 million sq. ft. of near-term
cultivation space and diversified growing and production
techniques. This is in addition to HEXO’s 579,000 sq.
ft. facility for a manufacturing and product development centre of
excellence in Belleville, Ontario. HEXO Corp has its headquarters
in Gatineau Canada, and it produces and sells most of its cannabis
products in the country.
The Brantford, Ontario-based Newstrike Brands were granted a
cultivation license on 16 December 2016, and the company expects
its harvest to be about 42,000 kg of cannabis. Although the company
has not been around for long compared to HEXO, it has high capacity
for cannabis production. HEXO recently announced that it had
completed the first harvest in its 1 million sq. ft. expansion,
marking an important execution milestone in the company's
continuous growth.
HEXO Corp., through its subsidiary, HEXO Operations Inc.,
produces, markets, and sells cannabis in Canada. The company
offers dried cannabis under the Time of Day and H2 lines; Elixir, a
cannabis oil sublingual mist product line; and Decarb, an activated
fine-milled cannabis powder product. It provides its products
under the HEXO and Hydropothecary brand names. The company
serves medical and adult-use markets. As one of the largest
licensed cannabis companies in Canada, HEXO Corp operates with
1.8 million sq. ft of facilities in Ontario and Quebec and a
foothold in Greece to establish a Eurozone processing, production
and distribution center.
_________
Auxly Cannabis Group Inc. (CBWTF) (Market Cap:
$363.713M; Share Price: $0.60) released its fourth
quarter and full year 2018 financial results in March 2019.
These filings and additional information regarding Auxly are
available for review on SEDAR. For the year ended December
31, 2018, Auxly recognized $747,000 of research revenues from the
recently completed acquisition of KGK in the third quarter of
2018. Auxly realized a gross loss of $188,000 in 2018
comprised of revenues less KGK expenses of $1,078,000 in support of
third-party research contracts.
On April 8, it announced that its wholly-owned subsidiary,
Robinsons Cannabis Inc. ("Robinsons"), has been granted standard
cultivation and processing licenses by Health Canada pursuant to
the Cannabis
Act and Cannabis
Regulations. The licenses give Robinsons the ability
to begin cultivation at its fully constructed 27,700 square-foot
facility in Kentville, Nova Scotia, which was purpose-built to
produce high-quality cannabis.
Auxly Cannabis Group Inc. operates as a cannabis streaming
company. It provides funding for cannabis production; and
holds contractual rights and minority equity interest relating to
the operation of cannabis facilities. The company was
formerly known as Cannabis Wheaton Income Corp. and changed its
name to Auxly Cannabis Group Inc. in June 2018. Auxly
Cannabis Group Inc. was incorporated in 1987 and is headquartered
in Vancouver, Canada.
________
Cara Therapeutics, Inc. (NASDAQ:
CARA) (Market Cap: $724.672M; Share Price:
$18.23), a clinical-stage biopharmaceutical company,
has a comprehensive report issued by Traders News Source, a leading
independent equity research and corporate access firm focused on
small and mid-cap public companies. Cara Therapeutics focuses
on developing and commercializing chemical entities with a primary
focus on pruritus and pain by selectively targeting kappa opioid
receptors.
Cara Therapeutics is a clinical-stage biopharmaceutical company
focused on developing and commercializing new chemical entities
with a primary focus on pruritus by selectively targeting
peripheral kappa opioid receptors (KORs). Cara is developing
a novel and proprietary class of product candidates, led by
KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body's peripheral nervous system, as well as
certain immune cells.
________
Signed by
Priyanka Goel, CFA
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting has agreed to a three-month
term consulting agreement with THCT dated 2/14/18. The
agreement calls for 50,000 restricted shares of THCT per month.
This agreement has been amended to $20,000 per month, and 55,000
shares per month and extended for twelve months ending 3/18/2020.
All payments were made directly by THC Therapeutics, Inc. to Regal
Consulting, LLC. to provide investor relations services, of which
this article is a part of. Regal Consulting also paid one
thousand dollars cash to microcapspeculators.com to distribute this
article. Regal Consulting may have a position in the securities
mentioned in this article at the time of publication, and may
increase or decrease its position without notice. This
article is based on public information and the opinions of Regal
Consulting. THCT was given an opportunity to edit this article.
This article contains forward-looking statements that are subject
to certain risks and uncertainties that could cause actual results
to differ materially from any results predicted herein. Regal
Consulting is not registered with any financial or securities
regulatory authority, and does not provide or claim to provide
investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click
Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
SOURCE: Microcap Speculators
Grafico Azioni THC Therapeutics (CE) (USOTC:THCT)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni THC Therapeutics (CE) (USOTC:THCT)
Storico
Da Ott 2023 a Ott 2024